Sarepta Therapeutics Inc

NASDAQ: SRPT
$114.23
+$3.73 (+3.4%)
Closing Price on November 22, 2024

SRPT Articles

Here are three biotechs that just recently announced successful Phase 2 trial data for drugs with very big addressable markets.
Sarepta Therapeutics Inc. (NASDAQ: SRPT) has seen more than its fair share of volatility in the market of late. Now shares are surging after it has reached a compromise with the U.S. Food and Drug...
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include First Data, General Electric, Sarepta Therapeutics, Western Digital, Walgreens Boots Alliance and Zillow.
Sarepta Therapeutics and Globalstar are among the companies that punished shareholder the most this past week.
Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares saw a handy gain on Wednesday following an analyst upgrade from Janney Montgomery Scott.
Several big FDA decisions should be coming up in the June quarter for the likes of AstraZeneca and Sarepta Therapeutics.
Apple, Twitter and other companies punished shareholders last week, and analysts expect more earnings disappointments going forward.
The top analyst upgrades, downgrades and initiations seen on Friday morning include Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital and Whiting Petroleum.
April 26, 2016: Here are four stocks trading with relatively heavy volume among 14 equities making new 52-week lows in Tuesday’s session. NYSE advancing stocks led decliners by about 3 to 1 while...
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Broadcom, Caterpillar, Sirius XM, Newmont, Palo Alto, Perrigo, Sarepta and Xerox.
Although the markets have made their comeback, some stocks are still slowing that recovery and punishing their shareholders. Last week that included Netflix and Sarepta Therapeutics.
Sarepta Therapeutics shares got crushed on Thursday and then exploded on Friday following the FDA view on its Duchenne muscular dystrophy treatment.
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include ArcelorMittal, Boeing, Intel, Johnson & Johnson, Schlumberger, Yahoo and Vivint Solar.
After a week when the indexes finally fought their way back to even for 2016, one probably would think that insiders would be selling the huge rally. Just the opposite happened.
24/7 Wall St. has collected three big FDA decisions coming up in February and added some color, along with the trading range and price target.